Tarang Sharma

Current mechanisms for assessing value of & payment for costly new drugs have led to limited access for patients. @TShealthpolicy et al argue for increased collaboration internationally and with patients in drug assessment bmj.com/content/391/bm… @WHO @helse_og_omsorg

NEW: Introducing @bmj_latest collection w/ @WHO_Europe @helse_og_omsorg “Access to novel medicines” bmj.com/collections/no… @WHO #WHONMP

Obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write @TrudoLemmens et al bmj.com/content/391/bm… @WHO @helse_og_omsorg @UTLaw

The high cost of new drugs—eg, cell, gene, and tissue therapies (ATMPs)—restricts patient access, increasing inequities & financial hardship. Read the new @bmj_latest collection w/ @WHO @helse_og_omsorg on action needed bmj.com/collections/no… #WHONMP

Pooled procurement and equity based tiered pricing. Zoltán Kaló et al consider systemic inequities, power imbalances arising from discrete national policies for drug pricing and reimbursement bmj.com/content/391/bm… @WHO @helse_og_omsorg @semmelweishu

Equitable access to novel medicines: Advanced therapies can improve population health only if they are procured at cost that delivers local value. By @bs_woods @tenHamR & Karl Claxton #BMJEditorial bmj.com/content/391/bm… @WHO @helse_og_omsorg

🌍 NEW @bmj_latest collection w/ @WHO_Europe @helse_og_omsorg “Access to novel medicines” bmj.com/collections/no… @WHO #WHONMP

As Dr Tedros says: "UHC is ultimately a political choice". Parliamentarians are crucial in making UHC happen - thank you @UHC2030 and UNITE 🙏🙏🙏

At the 20th Shanghai Forum, I spoke about how the WHO European Region is transforming health systems through digitalization & AI — and how we can partner with China 🇨🇳 to go even further, together. There is strong momentum in our Region to harness digital health and #AI. I firmly believe that working together with partners, including China, can significantly accelerate our progress. There are several promising areas for our collaboration with China. 🔹By leveraging AI, we can expand access to health care and improve its quality. 🔹By integrating AI into health education, we can equip future health professionals with the skills to apply AI tools and meet evolving needs. 🔹By establishing interregional pilot initiatives, we can test AI applications in real-world #health settings. Our partnership with #China in long-term and primary health care already demonstrates the power of shared learning. We can build on this foundation – using digitalization and AI to strengthen our health systems and improve lives across borders. #HealthForAll

After 1.5 years it was very fulfilling to see the hard work being brought to life this past week and see the ideas of the #WHONMP stakeholders that have the potential to change the status quo and improve access to patients. Looking forward to implementing @WHO_Europe

"There is a need to rebalance pharmaceutical systems in the European Region." @YNatsis explains how collaboration with different sectors is crucial if we want to ensure sustainable access to novel medicines in the European Region. 🔗 bit.ly/NMPjuly2024 #WHONMP @ESIP_EU

Enormous gratitude, whether @EFPIA or @ organisations, 4 your leadership & vision not to mention drive @hans_kluge. You have moved us from being divided in trenches to working together in the weeds. #Imagine what we can do together as a health community for #accesstomeds #WHONMP

Two days, 30 countries, six industry organizations, 12 partners, 14 NGOs. The Novel Medicines Platform is bringing all stakeholders to the same table to discuss how to improve access to novel medicines in the WHO European Region: bit.ly/3xSQNDw @natasha_azzmus #WHONMP

Transparency, innovation, commitment. The pillars underpinning the Novel Medicines Platform dialogue at @WHO_Europe. The NMP is precisely the policy lab we need to increase access to novel medicines, including those for rare diseases. 4/

Great start to Day 2 of @WHO_Europe #WHONMP consensus building mtg wt presentations from the working group focused on #transparency led by Francis Arickx with Sabine Volker & Kathleen Grieve of @MSDEurope for @EFPIA . Inspiring to see the work of all WGs to improve #accesstomeds

💊 💉 The Novel Medicines Platform is working to ensure fair access to novel medicines across the WHO European Region. Discover how on 2 July. Join us online 9:00 -10:20 AM CEST! 📹 🔴 bit.ly/NMPjuly2024 #WHONMP @hans_kluge @natasha_azzmus

@hans_kluge @natasha_azzmus Concerned about the high costs of novel medicines? So are we. That’s why we’re bringing together stakeholders to address this issue through the Novel Medicines Platform. TODAY: Join us live until 10:20 am CEST to learn more ➡️ bit.ly/NMPjuly2024 #WHONMP @natasha_azzmus

The demand for specialized drugs is rising, but high costs remain a challenge for countries. The Novel Medicines Platform will help countries improve access and sustainability of our health-care systems: bit.ly/4csfp5o #WHONMP

📌Topics discussed included, the need for solidarity to ensure sustainability, including horizon-scanning, managed entry agreements, early access, a focus on rare diseases and precision medicine, incentivizing R&D, and promoting equitable access across the Region.

Key takeaways: 📌The Novel Medicines Platform is a much-needed space for dialogue and collaboration. 📌It’s crucial for transforming health systems and advancing our shared goal of improving access to medicine and advancing #UniversalHealthCoverage.